Expanding the immunotherapy roadmap for hepatocellular carcinoma

Marina Baretti; Amy K. Kim; Robert A. Anders

doi:10.1016/j.ccell.2022.02.017

Expanding the immunotherapy roadmap for hepatocellular carcinoma

Marina Baretti, Amy K. Kim, Robert A. Anders

School of Medicine

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

In a recent Lancet Oncology article, Yau et al. report the CheckMate 459 trial results. This is the first phase III trial comparing the single-agent anti-programmed death protein 1 (PD-1) therapy nivolumab to the tyrosine kinase inhibitor sorafenib for treatment-naive patients with advanced hepatocellular carcinoma.

Original language	English (US)
Pages (from-to)	252-254
Number of pages	3
Journal	Cancer cell
Volume	40
Issue number	3
DOIs	https://doi.org/10.1016/j.ccell.2022.02.017
State	Published - Mar 14 2022

ASJC Scopus subject areas

Oncology
Cancer Research
Cell Biology

Access to Document

10.1016/j.ccell.2022.02.017

Cite this

@article{3d9142e756044d278664d123c134b07d,

title = "Expanding the immunotherapy roadmap for hepatocellular carcinoma",

abstract = "In a recent Lancet Oncology article, Yau et al. report the CheckMate 459 trial results. This is the first phase III trial comparing the single-agent anti-programmed death protein 1 (PD-1) therapy nivolumab to the tyrosine kinase inhibitor sorafenib for treatment-naive patients with advanced hepatocellular carcinoma.",

author = "Marina Baretti and Kim, {Amy K.} and Anders, {Robert A.}",

note = "Publisher Copyright: {\textcopyright} 2022 Elsevier Inc.",

year = "2022",

month = mar,

day = "14",

doi = "10.1016/j.ccell.2022.02.017",

language = "English (US)",

volume = "40",

pages = "252--254",

journal = "Cancer cell",

issn = "1535-6108",

publisher = "Cell Press",

number = "3",

}

TY - JOUR

T1 - Expanding the immunotherapy roadmap for hepatocellular carcinoma

AU - Baretti, Marina

AU - Kim, Amy K.

AU - Anders, Robert A.

PY - 2022/3/14

Y1 - 2022/3/14

N2 - In a recent Lancet Oncology article, Yau et al. report the CheckMate 459 trial results. This is the first phase III trial comparing the single-agent anti-programmed death protein 1 (PD-1) therapy nivolumab to the tyrosine kinase inhibitor sorafenib for treatment-naive patients with advanced hepatocellular carcinoma.

AB - In a recent Lancet Oncology article, Yau et al. report the CheckMate 459 trial results. This is the first phase III trial comparing the single-agent anti-programmed death protein 1 (PD-1) therapy nivolumab to the tyrosine kinase inhibitor sorafenib for treatment-naive patients with advanced hepatocellular carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=85125952225&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85125952225&partnerID=8YFLogxK

U2 - 10.1016/j.ccell.2022.02.017

DO - 10.1016/j.ccell.2022.02.017

M3 - Comment/debate

C2 - 35290785

AN - SCOPUS:85125952225

SN - 1535-6108

VL - 40

SP - 252

EP - 254

JO - Cancer cell

JF - Cancer cell

IS - 3

ER -

Expanding the immunotherapy roadmap for hepatocellular carcinoma

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this